Literature DB >> 14680452

Diquafosol tetrasodium: a novel dry eye therapy.

Kelly K Nichols1, Ben Yerxa, Donald J Kellerman.   

Abstract

The ophthalmic formulation of diquafosol tetrasodium (INS365), a P2Y2 receptor agonist, is targeted to treat dry eye disease through rehydration of the ocular surface. Existing pharmacological therapies for dry eye disease are limited, therefore, approval of this medication is anticipated. This review summarises key findings during development and in clinical trials including clinical effectiveness and safety. The relevance of P2Y2 receptor technology to dry eye disease and the disease process is discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14680452     DOI： 10.1517/13543784.13.1.47

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  22 in total

1.  Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction.

Authors:  Wan Namkung; Zhen Yao; Walter E Finkbeiner; A S Verkman
Journal:  FASEB J       Date:  2011-08-11       Impact factor: 5.191

2.  Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.

Authors:  Chika Shigeyasu; Masakazu Yamada; Yoko Akune; Kazuo Tsubota
Journal:  Jpn J Ophthalmol       Date:  2015-08-27       Impact factor: 2.447

Review 3.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 4.  [Current treatment for dry eye syndrome].

Authors:  C Cursiefen; C Jacobi; T Dietrich; F E Kruse
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

Review 5.  P2Y nucleotide receptors: promise of therapeutic applications.

Authors:  Kenneth A Jacobson; Jean-Marie Boeynaems
Journal:  Drug Discov Today       Date:  2010-06-02       Impact factor: 7.851

6.  Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye.

Authors:  Lian Cui; Ying Li; Hyo Seok Lee; Jee Myung Yang; Won Choi; Kyung Chul Yoon
Journal:  Int Ophthalmol       Date:  2017-08-18       Impact factor: 2.031

7.  Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study.

Authors:  K Kamiya; M Nakanishi; R Ishii; H Kobashi; A Igarashi; N Sato; K Shimizu
Journal:  Eye (Lond)       Date:  2012-08-10       Impact factor: 3.775

Review 8.  [Ophthalmological complications in Sjögren's syndrome].

Authors:  C Jacobi; C Cursiefen
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

9.  Expression of the P2Y₂ receptor on the rat ocular surface during a 1-year rearing period.

Authors:  Hidetoshi Tanioka; Yumi Kuriki; Asuka Sakamoto; Osamu Katsuta; Kouichi Kawazu; Masatsugu Nakamura
Journal:  Jpn J Ophthalmol       Date:  2014-09-02       Impact factor: 2.447

10.  Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives.

Authors:  Liesbet Cosyn; Serge Van Calenbergh; Bhalchandra V Joshi; Hyojin Ko; Rhonda L Carter; T Kendall Harden; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2009-04-14       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.